2019 CMCR Symposium

On Friday, October 18, 2019 the Center for Medicinal Cannabis Research (CMCR) held a one-day symposium celebrating the pioneers and exploring the progress, promise, and challenges of medicinal cannabis research. Click here to view an archive of the event broadcast.

Current CMCR studies

Current studies examine the effects of cannabis on pain and the potential benefits of CBD tinctures in the treatment of autistic children as well as public safety issues surrounding the use of cannabis and cannabinoids. The CMCR has recently funded 5 new research studies and as recruitment begins, the details of those studies can be found here.

CMCR announces $3M in new research grants to California investigators

The Center for Medicinal Cannabis Research (CMCR) at UC San Diego has been a leader in medical marijuana research since 2000. In the past CMCR has allocated funds to investigators in California to conduct some of the first proof of principle clinical trials of cannabis in neuropathic pain and multiple sclerosis. Learn more about the studies to be funded.

  • All
  • Announcements
  • Current Studies
  • Information
  • News
  • Presentations
  • Publications
  • Studies
  • Symposia
  • Default
  • Title
  • Date
  • Random
load more hold SHIFT key to load all load all

PI: Thomas Marcotte, Ph.D.

STUDY LOCATION: University of California, San Diego

PROJECT TITLE: A Randomized, Controlled Trial of Cannabis in Healthy Volunteers Evaluating Simulated Driving, Field Performance Tests and Cannabinoid Levels

PROJECT TYPE: Clinical Study

STATUS: Active

ABSTRACT:

This study was authorized by the California Legislature (Assembly Bill 266, the Medical Marijuana Regulation and Safety Act) to help with detection of driving under the influence of cannabis. Healthy volunteers will inhale smoked cannabis with either 0% (placebo), 6.7%, or 12.6% Δ9-THC at the beginning of the day, and then complete driving simulations, iPad-based performance assessments, and bodily fluid draws (e.g., blood, saliva, breath) before the cannabis smoking and hourly over the subsequent 7 hours after cannabis smoking. The purpose is to determine (1) the relationship of the dose of Δ9-THC on driving performance and (2) the duration of driving impairment in terms of hours from initial use, (3) if saliva or expired air can serve as a useful substitute for blood sampling of Δ9-THC in judicial hearings and (4) if testing using an iPad can serve as a useful adjunct to the standardized field sobriety test in identifying acute impairment from cannabis.